All In Biotech

Drug Trial Radar · NCT07583810

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

A Phase II Study of the Non-Covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab in Patients With Marginal Zone Lymphoma

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Oct 23, 2026

Primary completion

Sep 25, 2030

Study completion Sep 25, 2030

Sponsor

Lead sponsor
City of Hope Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
May 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests the effect of nemtabrutinib in combination with rituximab in treating patients with marginal zone lymphoma. Nemtabrutinib, a non-covalent Bruton's tyrosine kinase (BTK) inhibitor, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nemtabrutinib in combination with rituximab may be safe, tolerable and/or effective in treating patients with marginal zone lymphoma.

Conditions

  • Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma
  • Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
  • Marginal Zone Lymphoma
  • Nodal Marginal Zone Lymphoma
  • Splenic Marginal Zone Lymphoma
  • Lymphoma
  • Extranodal Marginal Zone Lymphoma

Interventions

  • Biopsy ProcedureProcedure

    Undergo tissue biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • Computed TomographyProcedure

    Undergo CT or PET/CT

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • NemtabrutinibDrug

    Given PO

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • RituximabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of unacceptable toxicity (Safety lead-in)Time frame: During cycle 1 (cycle length = 28 days)
  2. Complete response (CR) rate (Phase 2)Time frame: Up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.